CheckMab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CheckMab is a private, pre-revenue biotech firm leveraging monoclonal antibody technology for diagnostic and therapeutic applications in oncology and autoimmunity. Founded in 2006 and headquartered in Siena, Italy, the company appears to be in the pre-clinical or early development stage, focusing on translating its antibody expertise into novel tests and potential therapies. Its strategy involves partnerships to advance its programs, targeting significant unmet medical needs in cancer and autoimmune disease diagnostics.

OncologyAutoimmune Diseases

Technology Platform

Monoclonal antibody discovery and engineering for diagnostic test and therapeutic development.

Opportunities

The large and growing global markets for autoimmune and cancer diagnostics, coupled with the even larger therapeutic antibody market, present significant commercial opportunities.

The company's dual focus could allow for synergistic development of companion diagnostics alongside therapeutics.

Italy's strong academic biotech network offers collaboration and funding potential.

Risk Factors

High scientific risk in transitioning from diagnostics to effective therapies, and intense competition in both fields from large, established players.

Financial risk is acute as a pre-revenue, private company requiring continuous capital infusion to advance its pipeline without a near-term product launch.

Competitive Landscape

CheckMab competes in the crowded monoclonal antibody space. In diagnostics, it faces large IVD companies (e.g., Roche, Abbott, Siemens) and specialized diagnostic firms. In therapeutics, the competition is global biopharma giants (e.g., Roche/Genentech, Merck, AbbVie) and numerous biotech startups, all vying for novel targets and clinical success.

More companies in Biologics / Biosimilars →More companies in Italy →